SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (4739)4/23/1998 4:19:00 PM
From: biowa  Read Replies (1) of 9719
 
Henry,

>>Their partner for some of the progesterone analogs is AHP, who is more focused on the estrogen side (they have a $1 Billion Premarin market to protect). I'm not sure when progesterone analogs are slated to enter the clinic, but as can be seen from the table, many compounds should be just about finished with pre-clinical testing and are ready for IND filing.<<

I well understand the limitations of biotech R&D funding. I like to find opportunities in areas others aren't pursuing, and with every pharma in the world working on first, second and third generation SERMs, IMO SPRMs (Rman will have a field day with that pronunciation) might be an interesting angle. If you would please do me a favor and let me know of anything you hear from LGND on this I'd appreciate it. Anyone else know who's working on this area?

Thanks again, Henry.

biowa
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News